Bone marrow transplantation for myelodysplastic syndrome--who? when? and which? (Q34803700)

4 August 2017

1 reference

title

Bone marrow transplantation for myelodysplastic syndrome--who? when? and which? (English)

1 reference

4 August 2017

1 reference

Luger S

1 reference

4 August 2017

Sacks N

series ordinal

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Bone Marrow Transplantation

4 August 2017

published in

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

199-206

1 reference

Proposals for the classification of the myelodysplastic syndromes

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Bone marrow transplantation for myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of differe

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Successful peripheral blood stem cell transplantation for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Donor leucocyte transfusions for relapse in myelodyplastic syndrome after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703610

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703610

1 reference

Dimensions Publication ID

4 August 2017

1016263090

0 references

1 reference